Marketable Securities
 3 Months Ended
Apr. 30, 2017
Investments Debt And Equity Securities [Abstract]  
Marketable Securities

Note 3. Marketable Securities

At April 30, 2017, marketable securities consisted of the following (in thousands):

 

 

Amortized

 

 

Unrealized

 

 

Unrealized

 

 

Aggregate

 

 

 

Cost

 

 

Gains

 

 

Losses

 

 

Fair Value

 

Certificates of deposit

 

$

3,800

 

 

$

—

 

 

$

(3

)

 

$

3,797

 

Commercial paper

 

 

1,198

 

 

 

—

 

 

 

(1

)

 

 

1,197

 

Corporate bonds

 

 

18,018

 

 

 

—

 

 

 

(26

)

 

 

17,992

 

U.S. government agencies

 

 

2,002

 

 

 

—

 

 

 

(2

)

 

 

2,000

 

Money market funds

 

 

3,012

 

 

 

—

 

 

 

—

 

 

 

3,012

 

 

 

$

28,030

 

 

$

—

 

 

$

(32

)

 

$

27,998

 

Included in cash and cash equivalents

 

$

3,012

 

 

$

—

 

 

$

—

 

 

$

3,012

 

Included in short-term marketable securities

 

$

25,018

 

 

$

—

 

 

$

(32

)

 

$

24,986

 

 

At January 31, 2017, marketable securities consisted of the following (in thousands):

 

 

 

Amortized

 

 

Unrealized

 

 

Unrealized

 

 

Aggregate

 

 

 

Cost

 

 

Gains

 

 

Losses

 

 

Fair Value

 

Certificates of deposit

 

$

5,240

 

 

$

—

 

 

$

(3

)

 

$

5,237

 

Commercial paper

 

 

2,495

 

 

 

—

 

 

 

(2

)

 

 

2,493

 

Corporate bonds

 

 

16,827

 

 

 

—

 

 

 

(24

)

 

 

16,803

 

U.S. government agencies

 

 

2,002

 

 

 

—

 

 

 

(1

)

 

 

2,001

 

Money market funds

 

 

1,433

 

 

 

—

 

 

 

—

 

 

 

1,433

 

Total

 

$

27,997

 

 

$

—

 

 

$

(30

)

 

$

27,967

 

Included in cash and cash equivalents

 

$

1,433

 

 

$

—

 

 

$

—

 

 

$

1,433

 

Included in short-term marketable securities

 

$

26,564

 

 

$

—

 

 

$

(30

)

 

$

26,534

 

 

The Company considers the declines in market value of its marketable securities investment portfolio to be temporary in nature. When evaluating an investment for other-than-temporary impairment, the Company reviews factors such as the length of time and extent to which fair value has been below its cost basis, the financial condition of the issuer and any changes thereto, changes in market interest rates and the Company’s intent to sell, or whether it is more likely than not it will be required to sell the investment before recovery of the investment’s cost basis. As of April 30, 2017, the Company does not consider any of its investments to be other-than-temporarily impaired. The Company classifies its marketable securities as available-for-sale at the time of purchase and reevaluates such classification as of each balance sheet date. The Company may sell these securities at any time for use in current operations or for other purposes, such as consideration for acquisitions, even if they have not yet reached maturity. As a result, the Company classifies its investments, including securities with maturities beyond twelve months as “current assets” in the accompanying condensed consolidated balance sheets. Marketable securities on the condensed consolidated balance sheets consist of securities with original maturities at the time of purchase greater than three months and the remaining securities are reflected in cash and cash equivalents. During the three months ended April 30, 2017, the Company did not sell any of its marketable securities.